» Articles » PMID: 39463906

Multisystem Inflammatory Syndrome in Children: A Case Report

Overview
Journal Cureus
Date 2024 Oct 28
PMID 39463906
Authors
Affiliations
Soon will be listed here.
Abstract

This case report delves into the case of a patient in the Dominican Republic with multisystem inflammatory syndrome in children (MIS-C). MIS-C is a rare, hyper-inflammatory condition that develops in children as a delayed response to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, typically appearing with general markers of inflammation such as erythema and, in severe cases, cardiorespiratory symptoms. The three-year-old patient discussed in this report presented with signs of inflammation, such as erythema, rashes, and chapped skin, and reported experiencing diarrhea, vomiting, and fever for multiple days. Notably, a concurrent parasitic presence was found in the patient's fecal sample, and antibiotics were heavily used throughout the course of treatment. We explain the merits and drawbacks behind using antibiotic therapy for MIS-C and suggest steps that clinicians and researchers can take in order to minimize the potential misuse of antibiotics. Specifically, we identify that prioritizing tests for concurrent infections or illnesses is imperative in treating MIS-C patients, and we conclude by stating that using blood cultures and coprological examinations in tandem is an effective strategy for this purpose.

References
1.
Mahmoud S, El-Kalliny M, Kotby A, El-Ganzoury M, Fouda E, Ibrahim H . Treatment of MIS-C in Children and Adolescents. Curr Pediatr Rep. 2022; 10(1):1-10. PMC: 8741532. DOI: 10.1007/s40124-021-00259-4. View

2.
Diorio C, Shraim R, Vella L, Giles J, Baxter A, Oldridge D . Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat Commun. 2021; 12(1):7222. PMC: 8664884. DOI: 10.1038/s41467-021-27544-6. View

3.
Iyer S, Cheng G . Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012; 32(1):23-63. PMC: 3410706. DOI: 10.1615/critrevimmunol.v32.i1.30. View

4.
Day-Lewis M, Berbert L, Baker A, Dionne A, Newburger J, Son M . Updated Case Definition of MIS-C and Implications for Clinical Care. Pediatrics. 2024; 153(2). DOI: 10.1542/peds.2023-063259. View

5.
Vankova L, Bufka J, Krizkova V . Pathophysiological and clinical point of view on Kawasaki disease and MIS-C. Pediatr Neonatol. 2023; 64(5):495-504. PMC: 10286520. DOI: 10.1016/j.pedneo.2023.05.002. View